- Home
- THQ vs PSNL Comparison
THQ vs PSNL Comparison
Compare THQ & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | THQ | PSNL |
|---|---|---|
| Founded | 2014 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 755.7M | 729.1M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | THQ | PSNL |
|---|---|---|
| Price | $18.00 | $6.62 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $11.50 |
| AVG Volume (30 Days) | 110.0K | ★ 1.2M |
| Earning Date | 01-01-0001 | 05-18-2026 |
| Dividend Yield | ★ 7.53% | N/A |
| EPS Growth | N/A | ★ 33.58 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $69,648,000.00 |
| Revenue This Year | N/A | $16.94 |
| Revenue Next Year | N/A | $36.58 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $15.14 | $2.83 |
| 52 Week High | $21.07 | $11.50 |
Technical Indicators
Market Signals| Indicator | THQ | PSNL |
|---|---|---|
| Relative Strength Index (RSI) | 29.02 | 32.87 |
| Support Level | $17.68 | $4.31 |
| Resistance Level | $18.36 | $6.94 |
| Average True Range (ATR) | 0.26 | 0.71 |
| MACD | -0.10 | -0.15 |
| Stochastic Oscillator | 5.80 | 0.17 |
Price Performance
Historical ComparisonAbout THQ abrdn Healthcare Opportunities Fund Shares of Beneficial Interest
abrdn Healthcare Opportunities Fund is a non-diversified closed-end fund in the United States. Its investment objective is to seek current income and long-term capital appreciation through investments in U.S. and non-U.S. companies. The fund invests in equity and debt securities of public and private healthcare companies believed by the Fund's Adviser to have potential for above-average growth, and may invest in private companies and other restricted securities, including private investments in public equity and venture capital investments, provided these securities comprise 10% or less of Managed Assets.
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.